Details of the Drug Combinations

General Information of This Drug (ID: DMP6G8T)

Drug Name
Topotecan   DMP6G8T
Synonyms
Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin
Indication
Disease Entry ICD 11 Status REF
Central nervous system neoplasm N.A. Approved [1]
Cervical cancer 2C77.0 Approved [1]
Epithelial ovarian cancer 2B5D Approved [1]
Lung cancer 2C25.0 Approved [1]
Ovarian cancer 2C73 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Small-cell lung cancer 2C25.Y Phase 1 [4]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1416 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Topotecan DC0U7DK ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
ABIRATERONE + Topotecan DCLRNO8 ABIRATERONE Astrocytoma (Cell Line: SNB-19) [5]
ABIRATERONE + Topotecan DC04AQH ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
ABIRATERONE + Topotecan DC7JS8J ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
ABIRATERONE + Topotecan DCLINMV ABIRATERONE Carcinoma (Cell Line: MCF7) [6]
ABIRATERONE + Topotecan DCW9G53 ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [6]
ABIRATERONE + Topotecan DCKU0HV ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
ABIRATERONE + Topotecan DCQJ5Z7 ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
ABIRATERONE + Topotecan DCSKQUX ABIRATERONE Lung adenocarcinoma (Cell Line: EKVX) [7]
ABIRATERONE + Topotecan DCLA0LL ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
ABIRATERONE + Topotecan DCSG4KC ABIRATERONE Melanoma (Cell Line: MALME-3M) [7]
ABIRATERONE + Topotecan DC68RAI ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
ABIRATERONE + Topotecan DCYWTIV ABIRATERONE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
ABIRATERONE + Topotecan DCLU4IU ABIRATERONE Prostate carcinoma (Cell Line: PC-3) [7]
Acamprosate + Topotecan DCQNIGF Acamprosate Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Acetohydroxamic Acid + Topotecan DCZV00O Acetohydroxamic Acid Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Amiloride + Topotecan DC4KEAE Amiloride Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Amonafide + Topotecan DCL4KW8 Amonafide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Amonafide + Topotecan DCUU39C Amonafide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Amonafide + Topotecan DC2DYRD Amonafide Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Amonafide + Topotecan DC2ZY93 Amonafide Glioma (Cell Line: SF-268) [5]
Amonafide + Topotecan DCOTECA Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Amonafide + Topotecan DCP6CH7 Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Amonafide + Topotecan DCKV1G9 Amonafide Melanoma (Cell Line: MALME-3M) [5]
Amonafide + Topotecan DCMKMLZ Amonafide Melanoma (Cell Line: UACC-257) [5]
Amonafide + Topotecan DCOLL2U Amonafide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Amonafide + Topotecan DCXY910 Amonafide Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Anastrozole + Topotecan DCF18LA Anastrozole Adenocarcinoma (Cell Line: OVCAR3) [5]
Anastrozole + Topotecan DCPCEKO Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Anastrozole + Topotecan DCOA4AS Anastrozole Astrocytoma (Cell Line: SNB-19) [5]
Anastrozole + Topotecan DC5G0RH Anastrozole Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Anastrozole + Topotecan DCDFIKF Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Anastrozole + Topotecan DCMMNUP Anastrozole Glioblastoma (Cell Line: SNB-75) [5]
Anastrozole + Topotecan DCJACL5 Anastrozole Glioma (Cell Line: SF-268) [5]
Anastrozole + Topotecan DC6Q7NE Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Anastrozole + Topotecan DCHSSPI Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Anastrozole + Topotecan DC4S9BS Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Anastrozole + Topotecan DCMM2B4 Anastrozole Lung adenocarcinoma (Cell Line: EKVX) [5]
Anastrozole + Topotecan DCI6WN6 Anastrozole Malignant melanoma (Cell Line: LOX IMVI) [5]
Anastrozole + Topotecan DCHU5QO Anastrozole Melanoma (Cell Line: MALME-3M) [5]
Anastrozole + Topotecan DCTNAGA Anastrozole Melanoma (Cell Line: UACC-257) [5]
Anastrozole + Topotecan DCWPWW3 Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Anastrozole + Topotecan DCFB4IJ Anastrozole Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Anastrozole + Topotecan DC2DFV4 Anastrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Anastrozole + Topotecan DCH7W0W Anastrozole Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Anastrozole + Topotecan DC6GXEZ Anastrozole Prostate carcinoma (Cell Line: PC-3) [5]
Anastrozole + Topotecan DCMMPEX Anastrozole Renal cell carcinoma (Cell Line: SN12C) [5]
Anastrozole + Topotecan DCLK1FS Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Anastrozole + Topotecan DCG08CI Anastrozole Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Aprepitant + Topotecan DCKZVEY Aprepitant Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Asenapine + Topotecan DCGKD9U Asenapine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Azatadine + Topotecan DC8X7V4 Azatadine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
BIO-300 + Topotecan DCYMMQU BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
BIO-300 + Topotecan DCMRLIG BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
BIO-300 + Topotecan DC1TN9I BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [5]
BIO-300 + Topotecan DCMCXOG BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
BIO-300 + Topotecan DCYZTV0 BIO-300 Glioblastoma (Cell Line: SNB-75) [5]
BIO-300 + Topotecan DCB3UOL BIO-300 Glioma (Cell Line: SF-268) [5]
BIO-300 + Topotecan DCJE906 BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
BIO-300 + Topotecan DCY7NT1 BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [7]
BIO-300 + Topotecan DCH6ZD9 BIO-300 Melanoma (Cell Line: UACC-257) [7]
BIO-300 + Topotecan DCIT2P9 BIO-300 Melanoma (Cell Line: MALME-3M) [7]
Bleomycin + Topotecan DCFPY92 Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Bleomycin + Topotecan DCP5X77 Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Bleomycin + Topotecan DCOFVXM Bleomycin Astrocytoma (Cell Line: SNB-19) [5]
Bleomycin + Topotecan DCM19H9 Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Bleomycin + Topotecan DCKNJ9O Bleomycin Glioblastoma (Cell Line: SNB-75) [5]
Bleomycin + Topotecan DC42A3N Bleomycin Glioma (Cell Line: SF-268) [5]
Bleomycin + Topotecan DCL7SLT Bleomycin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Bleomycin + Topotecan DC228VE Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Bleomycin + Topotecan DCYT0BA Bleomycin Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Bleomycin + Topotecan DCWJRFL Bleomycin Adenocarcinoma (Cell Line: DU-145) [7]
Bleomycin + Topotecan DC5KX0E Bleomycin Adenocarcinoma (Cell Line: OVCAR3) [7]
Bleomycin + Topotecan DCU49QO Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Bleomycin + Topotecan DCL44KQ Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Bleomycin + Topotecan DCJWKKN Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Bleomycin + Topotecan DC9QOMI Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [7]
Bleomycin + Topotecan DCX29RC Bleomycin Melanoma (Cell Line: MALME-3M) [7]
Bleomycin + Topotecan DCTNIQO Bleomycin Melanoma (Cell Line: UACC-257) [7]
Bleomycin + Topotecan DC7LPGE Bleomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Bleomycin + Topotecan DCT69VW Bleomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Bleomycin + Topotecan DC9S15D Bleomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Bleomycin + Topotecan DCDAAXU Bleomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Bortezomib + Topotecan DCM27H8 Bortezomib Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Cabazitaxel + Topotecan DC9XCTQ Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [5]
Cabazitaxel + Topotecan DC733ZB Cabazitaxel Adenocarcinoma (Cell Line: A549) [5]
Cabazitaxel + Topotecan DCPQSNT Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [5]
Cabazitaxel + Topotecan DC77QJB Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [5]
Cabazitaxel + Topotecan DCLPKXU Cabazitaxel Adenocarcinoma (Cell Line: HT29) [5]
Cabazitaxel + Topotecan DCJV2VM Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Cabazitaxel + Topotecan DCP76E4 Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Cabazitaxel + Topotecan DCGPTS1 Cabazitaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Cabazitaxel + Topotecan DC2KM9B Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [5]
Cabazitaxel + Topotecan DCU7BHZ Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Cabazitaxel + Topotecan DCDBBC9 Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Cabazitaxel + Topotecan DCPYWZS Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Cabazitaxel + Topotecan DC8SDK5 Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Cabazitaxel + Topotecan DCST11K Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Cabazitaxel + Topotecan DCPI208 Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Cabazitaxel + Topotecan DC7FVCZ Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [5]
Cabazitaxel + Topotecan DC3GZX5 Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [5]
Cabazitaxel + Topotecan DCYDTDK Cabazitaxel Carcinoma (Cell Line: RXF 393) [6]
Cabazitaxel + Topotecan DC3UPMD Cabazitaxel Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Cefmenoxime + Topotecan DCC80WZ Cefmenoxime Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Cerivastatin + Topotecan DC4LEBD Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Crizotinib + Topotecan DCRA2OR Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Crizotinib + Topotecan DC2POKS Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Crizotinib + Topotecan DCR24DS Crizotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Crizotinib + Topotecan DCCXT05 Crizotinib Astrocytoma (Cell Line: SNB-19) [5]
Crizotinib + Topotecan DCL15VD Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Crizotinib + Topotecan DCWX62J Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Crizotinib + Topotecan DCJJVPF Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Crizotinib + Topotecan DCM7AAA Crizotinib Glioma (Cell Line: SF-268) [5]
Crizotinib + Topotecan DC4XODQ Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Crizotinib + Topotecan DCY52EB Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Crizotinib + Topotecan DCFSMXP Crizotinib Melanoma (Cell Line: MALME-3M) [5]
Crizotinib + Topotecan DCMA5T6 Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Crizotinib + Topotecan DCLUWW3 Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Crizotinib + Topotecan DCZASUN Crizotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Crizotinib + Topotecan DCM1X4G Crizotinib Prostate carcinoma (Cell Line: PC-3) [5]
Crizotinib + Topotecan DCDHFXM Crizotinib Renal cell carcinoma (Cell Line: UO-31) [5]
Crizotinib + Topotecan DCRK8ZG Crizotinib Carcinoma (Cell Line: MCF7) [6]
Crizotinib + Topotecan DCHOKHK Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Dacarbazine + Topotecan DCJA7ZD Dacarbazine Adenocarcinoma (Cell Line: OVCAR3) [5]
Dacarbazine + Topotecan DCLDNDY Dacarbazine Adenocarcinoma (Cell Line: HT29) [5]
Dacarbazine + Topotecan DC3UP3T Dacarbazine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dacarbazine + Topotecan DC9TE6J Dacarbazine Astrocytoma (Cell Line: SNB-19) [5]
Dacarbazine + Topotecan DCO4LVH Dacarbazine Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Dacarbazine + Topotecan DCZPJUH Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Dacarbazine + Topotecan DCILXJH Dacarbazine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Dacarbazine + Topotecan DCO7JZH Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Dacarbazine + Topotecan DCXYK85 Dacarbazine Glioma (Cell Line: SF-268) [5]
Dacarbazine + Topotecan DCJK9CT Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Dacarbazine + Topotecan DCC1LYL Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Dacarbazine + Topotecan DCQMRJB Dacarbazine Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Dacarbazine + Topotecan DCWTMWY Dacarbazine Lung adenocarcinoma (Cell Line: EKVX) [5]
Dacarbazine + Topotecan DCX2TTK Dacarbazine Melanoma (Cell Line: UACC-257) [5]
Dacarbazine + Topotecan DC2CK9A Dacarbazine Melanoma (Cell Line: MALME-3M) [5]
Dacarbazine + Topotecan DCSZ3BY Dacarbazine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Dacarbazine + Topotecan DCIVB3M Dacarbazine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Dacarbazine + Topotecan DCBSUWB Dacarbazine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Dacarbazine + Topotecan DCYT5IS Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Daidzin + Topotecan DCRIFMQ Daidzin Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Dantrolene + Topotecan DCBNIBQ Dantrolene Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Dexrazoxane + Topotecan DCQO4QW Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Dexrazoxane + Topotecan DC1KJRL Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Dexrazoxane + Topotecan DCY04EN Dexrazoxane Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Dexrazoxane + Topotecan DCAIHWX Dexrazoxane Glioblastoma (Cell Line: SNB-75) [5]
Dexrazoxane + Topotecan DCC9ZKZ Dexrazoxane Glioma (Cell Line: SF-268) [5]
Dexrazoxane + Topotecan DCS8TWL Dexrazoxane Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Dexrazoxane + Topotecan DC12OS2 Dexrazoxane Renal cell carcinoma (Cell Line: SN12C) [5]
Dexrazoxane + Topotecan DC4YS83 Dexrazoxane Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Dexrazoxane + Topotecan DCN4OL1 Dexrazoxane Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Dexrazoxane + Topotecan DCQ9JYV Dexrazoxane Adenocarcinoma (Cell Line: OVCAR3) [7]
Dexrazoxane + Topotecan DC3M7N1 Dexrazoxane Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Dexrazoxane + Topotecan DCRKGAT Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Dexrazoxane + Topotecan DCLM791 Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Dexrazoxane + Topotecan DCNK5CW Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Dexrazoxane + Topotecan DCKALVC Dexrazoxane Lung adenocarcinoma (Cell Line: EKVX) [7]
Dexrazoxane + Topotecan DC23PKH Dexrazoxane Melanoma (Cell Line: MALME-3M) [7]
Dexrazoxane + Topotecan DCBVZTH Dexrazoxane Melanoma (Cell Line: UACC-257) [7]
Dexrazoxane + Topotecan DC7HPO6 Dexrazoxane Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Dexrazoxane + Topotecan DCQYNO1 Dexrazoxane Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Dexrazoxane + Topotecan DC6EQAL Dexrazoxane Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Dopamine + Topotecan DCGRSN4 Dopamine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Epinephrine + Topotecan DC8JFE9 Epinephrine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Epirubicin + Topotecan DCBASI9 Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Epirubicin + Topotecan DC8HZFB Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Epirubicin + Topotecan DCTRP8V Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Epirubicin + Topotecan DCWRLF5 Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Epirubicin + Topotecan DC27WT2 Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Epirubicin + Topotecan DC9YDRI Epirubicin Carcinoma (Cell Line: RXF 393) [6]
Epirubicin + Topotecan DCNJM9M Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Epirubicin + Topotecan DCJ8V4D Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Epirubicin + Topotecan DCR550O Epirubicin Melanoma (Cell Line: MALME-3M) [7]
Epirubicin + Topotecan DC4ZRNL Epirubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Epirubicin + Topotecan DCH5P6P Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Epirubicin + Topotecan DCX26MK Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Epirubicin + Topotecan DCITL8F Epirubicin Prostate carcinoma (Cell Line: PC-3) [7]
Ethambutol + Topotecan DC2QPYJ Ethambutol Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Fibrates + Topotecan DCWSNOW Fibrates Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Fluorouracil + Topotecan DCMTG98 Fluorouracil Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [5]
Fluorouracil + Topotecan DCQFPBN Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Fluorouracil + Topotecan DCVXN69 Fluorouracil Colon adenocarcinoma (Cell Line: LOVO) [6]
Fluorouracil + Topotecan DCSN8PB Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [6]
Fluorouracil + Topotecan DCZM2PH Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [7]
Fluorouracil + Topotecan DC25NR0 Fluorouracil Adenocarcinoma (Cell Line: A427) [7]
Fluorouracil + Topotecan DC661LB Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [7]
Fluorouracil + Topotecan DCUL2DD Fluorouracil Adenocarcinoma (Cell Line: COLO320DM) [7]
Fluorouracil + Topotecan DC633RQ Fluorouracil Adenocarcinoma (Cell Line: DLD1) [7]
Fluorouracil + Topotecan DCOS8R7 Fluorouracil Adenocarcinoma (Cell Line: HT29) [7]
Fluorouracil + Topotecan DCN7AI7 Fluorouracil Adenocarcinoma (Cell Line: SW-620) [7]
Fluorouracil + Topotecan DCC80SK Fluorouracil Amelanotic melanoma (Cell Line: A2058) [7]
Fluorouracil + Topotecan DCEVR8X Fluorouracil Germ cell tumour (Cell Line: PA1) [7]
Fluorouracil + Topotecan DCUVC7L Fluorouracil Malignant melanoma (Cell Line: A375) [7]
Fluorouracil + Topotecan DCMZYDR Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [7]
Fluorouracil + Topotecan DC9P84L Fluorouracil Malignant melanoma (Cell Line: SKMEL30) [7]
Fluorouracil + Topotecan DCUL5L3 Fluorouracil Malignant melanoma (Cell Line: UACC62) [7]
Fluorouracil + Topotecan DCT0S2E Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Fomepizole + Topotecan DCHVBL1 Fomepizole Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Gefitinib + Topotecan DCWQBCG Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Gefitinib + Topotecan DC28B19 Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Gefitinib + Topotecan DCLL989 Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Gefitinib + Topotecan DCFC9RK Gefitinib Glioma (Cell Line: SF-268) [5]
Gefitinib + Topotecan DC1GVT3 Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Gefitinib + Topotecan DCLDHBI Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Gefitinib + Topotecan DC4A1AD Gefitinib Melanoma (Cell Line: UACC-257) [5]
Gefitinib + Topotecan DCKB3V5 Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Gefitinib + Topotecan DC4HSLM Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Gefitinib + Topotecan DCPRZC4 Gefitinib Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Gefitinib + Topotecan DCRQ68K Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Gefitinib + Topotecan DCKM2IX Gefitinib Prostate carcinoma (Cell Line: PC-3) [5]
Gefitinib + Topotecan DCRRP41 Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Gefitinib + Topotecan DC6T4MD Gefitinib Carcinoma (Cell Line: MCF7) [6]
Gefitinib + Topotecan DC540ZY Gefitinib Colon adenocarcinoma (Cell Line: COLO 205) [6]
Gefitinib + Topotecan DCWDY5M Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Ginsenoside Rb1 + Topotecan DCKMMTQ Ginsenoside Rb1 Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Indazole derivative 5 + Topotecan DCON5CJ Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Indazole derivative 5 + Topotecan DC9YGCX Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Indazole derivative 5 + Topotecan DC2BNOM Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Indazole derivative 5 + Topotecan DCMFRR2 Indazole derivative 5 Glioma (Cell Line: SF-268) [5]
Indazole derivative 5 + Topotecan DCWJQ5B Indazole derivative 5 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Indazole derivative 5 + Topotecan DCN3EKC Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Indazole derivative 5 + Topotecan DCT3KZB Indazole derivative 5 Carcinoma (Cell Line: MCF7) [6]
Indazole derivative 5 + Topotecan DCZY7A4 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [6]
Indazole derivative 5 + Topotecan DCLDV8J Indazole derivative 5 Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Indazole derivative 5 + Topotecan DCMBLB9 Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Indazole derivative 5 + Topotecan DC2XWA1 Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Indazole derivative 5 + Topotecan DCD3UP4 Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Indazole derivative 5 + Topotecan DCXTOD2 Indazole derivative 5 Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Indazole derivative 5 + Topotecan DC47JNC Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [7]
Indazole derivative 5 + Topotecan DCMC289 Indazole derivative 5 Melanoma (Cell Line: UACC-257) [7]
Indazole derivative 5 + Topotecan DC8FJ3G Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Indazole derivative 5 + Topotecan DCFCJWW Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Indazole derivative 5 + Topotecan DCY64ET Indazole derivative 5 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Indazole derivative 5 + Topotecan DCCQXYW Indazole derivative 5 Prostate carcinoma (Cell Line: PC-3) [7]
Isosorbide dinitrate + Topotecan DCJWL8D Isosorbide dinitrate Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
L-165041 + Topotecan DC3L1BI L-165041 Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Leflunomide + Topotecan DC0VI14 Leflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Lenalidomide + Topotecan DCFOJYB Lenalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Lenalidomide + Topotecan DCTXHJK Lenalidomide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Lenalidomide + Topotecan DC7VR2D Lenalidomide Glioma (Cell Line: SF-268) [5]
Lenalidomide + Topotecan DCN4KVC Lenalidomide Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Lenalidomide + Topotecan DCSHYS4 Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Lenalidomide + Topotecan DCGECA3 Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Lenalidomide + Topotecan DCJ0OWX Lenalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Lenalidomide + Topotecan DCDF6RC Lenalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Lenalidomide + Topotecan DCNYHA2 Lenalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Lenalidomide + Topotecan DCPYBLU Lenalidomide Lung adenocarcinoma (Cell Line: EKVX) [7]
Lenalidomide + Topotecan DCYI24Q Lenalidomide Melanoma (Cell Line: UACC-257) [7]
Lenalidomide + Topotecan DCPVLXW Lenalidomide Melanoma (Cell Line: MALME-3M) [7]
Lenalidomide + Topotecan DCEDB27 Lenalidomide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Lenalidomide + Topotecan DCI83ZM Lenalidomide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Levamisole + Topotecan DC0299H Levamisole Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
LY03004 + Topotecan DCXW328 LY03004 Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Mechlorethamine + Topotecan DC4V9VY Mechlorethamine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Mechlorethamine + Topotecan DCMC452 Mechlorethamine Glioma (Cell Line: SF-268) [5]
Mechlorethamine + Topotecan DCO57HY Mechlorethamine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Mechlorethamine + Topotecan DC2Q8TC Mechlorethamine Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Mechlorethamine + Topotecan DC7W0Y4 Mechlorethamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Mechlorethamine + Topotecan DCU364D Mechlorethamine Lung adenocarcinoma (Cell Line: EKVX) [7]
Mechlorethamine + Topotecan DCKI2X6 Mechlorethamine Melanoma (Cell Line: UACC-257) [7]
Mechlorethamine + Topotecan DCGL3SR Mechlorethamine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Mechlorethamine + Topotecan DCDAX35 Mechlorethamine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Mechlorethamine + Topotecan DCR5YQQ Mechlorethamine Prostate carcinoma (Cell Line: PC-3) [7]
Metaxalone + Topotecan DC5PF6D Metaxalone Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Methylene blue + Topotecan DCDN30W Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Miglustat + Topotecan DC8DJTV Miglustat Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Nizatidine + Topotecan DC6B29U Nizatidine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Oseltamivir + Topotecan DCF8F59 Oseltamivir Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Pentamidine + Topotecan DCETIPX Pentamidine Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Probenecid + Topotecan DCMBH8X Probenecid Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Raloxifene + Topotecan DC02ERB Raloxifene Glioma (Cell Line: SF-268) [5]
Raloxifene + Topotecan DCJK59J Raloxifene Glioma (Cell Line: SF-539) [5]
Raloxifene + Topotecan DCRCO3H Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [6]
Raloxifene + Topotecan DCL09U6 Raloxifene Adenocarcinoma (Cell Line: NCIH23) [7]
Raloxifene + Topotecan DC1XPJV Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [7]
Raloxifene + Topotecan DCFJZN2 Raloxifene Adenocarcinoma (Cell Line: SW-620) [7]
Raloxifene + Topotecan DCY1R5F Raloxifene Adenocarcinoma (Cell Line: HCT-15) [7]
Raloxifene + Topotecan DCMHJ22 Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Raloxifene + Topotecan DCULWHT Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [7]
Raloxifene + Topotecan DC1GRUD Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Raloxifene + Topotecan DCF0OTT Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Raloxifene + Topotecan DC7FY87 Raloxifene Melanoma (Cell Line: MALME-3M) [7]
Raloxifene + Topotecan DCJYOZ9 Raloxifene Melanoma (Cell Line: SK-MEL-2) [7]
Raloxifene + Topotecan DC2DJBB Raloxifene Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Raloxifene + Topotecan DCCLW61 Raloxifene Prostate carcinoma (Cell Line: PC-3) [7]
Ruxolitinib + Topotecan DC1H4NB Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Ruxolitinib + Topotecan DCCFLLS Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Ruxolitinib + Topotecan DCYK2KA Ruxolitinib Carcinoma (Cell Line: MCF7) [6]
Ruxolitinib + Topotecan DCGHSW6 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Ruxolitinib + Topotecan DCVCB1S Ruxolitinib Lung adenocarcinoma (Cell Line: EKVX) [7]
Ruxolitinib + Topotecan DCF52RI Ruxolitinib Melanoma (Cell Line: MALME-3M) [7]
Ruxolitinib + Topotecan DCXL6TB Ruxolitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Ruxolitinib + Topotecan DCI2W3U Ruxolitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Ruxolitinib + Topotecan DCQSO68 Ruxolitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Testosterone + Topotecan DCMXFCX Testosterone Chronic myelogenous leukemia (Cell Line: KBM-7) [5]
Thioguanine + Topotecan DCR36KB Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Thioguanine + Topotecan DCUXBB1 Thioguanine Astrocytoma (Cell Line: SNB-19) [5]
Thioguanine + Topotecan DCO6FK3 Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Thioguanine + Topotecan DCCCKQN Thioguanine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Thioguanine + Topotecan DCV8MK2 Thioguanine Glioblastoma (Cell Line: SNB-75) [5]
Thioguanine + Topotecan DCLP4SC Thioguanine Glioma (Cell Line: SF-268) [5]
Thioguanine + Topotecan DCT8MFN Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Thioguanine + Topotecan DCNM71M Thioguanine Renal cell carcinoma (Cell Line: SN12C) [5]
Thioguanine + Topotecan DCMBPK1 Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Thioguanine + Topotecan DC8KWT6 Thioguanine Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Thioguanine + Topotecan DCWL6X1 Thioguanine Adenocarcinoma (Cell Line: OVCAR3) [7]
Thioguanine + Topotecan DCTCS5J Thioguanine Adenocarcinoma (Cell Line: A549) [7]
Thioguanine + Topotecan DCZ7OV1 Thioguanine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Thioguanine + Topotecan DCW6GEV Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Thioguanine + Topotecan DCQE82K Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Thioguanine + Topotecan DCGGG08 Thioguanine Lung adenocarcinoma (Cell Line: EKVX) [7]
Thioguanine + Topotecan DCSLZDJ Thioguanine Melanoma (Cell Line: UACC-257) [7]
Thioguanine + Topotecan DCCFPN8 Thioguanine Melanoma (Cell Line: MALME-3M) [7]
Thioguanine + Topotecan DCYA3PP Thioguanine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Thioguanine + Topotecan DCO76B7 Thioguanine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Thioguanine + Topotecan DC5W0CI Thioguanine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Fulvestrant DC96C9E Fulvestrant Carcinoma (Cell Line: MCF7) [6]
Topotecan + PD-0325901 DCW2QXV PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + PD-0325901 DCK95OC PD-0325901 Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + PD-0325901 DCFKX6L PD-0325901 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + PD-0325901 DC21YB4 PD-0325901 Carcinoma (Cell Line: MDAMB436) [6]
Topotecan + PD-0325901 DCQH694 PD-0325901 Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + PD-0325901 DCL9DWF PD-0325901 Colon carcinoma (Cell Line: RKO) [6]
Topotecan + PD-0325901 DCYVPIH PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Hepzato DC23Q9V Hepzato Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Hepzato DC47SHB Hepzato Carcinoma (Cell Line: MCF7) [6]
Topotecan + Ixabepilone DCJY3VL Ixabepilone Carcinoma (Cell Line: MCF7) [6]
Topotecan + Dactinomycin DCPW21K Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Dactinomycin DCPC2BJ Dactinomycin Carcinoma (Cell Line: RXF 393) [6]
Topotecan + Dactinomycin DC2V2LW Dactinomycin Carcinoma (Cell Line: MCF7) [6]
Topotecan + Dactinomycin DCC54NP Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + DFN-15 DCMODTR DFN-15 Carcinoma (Cell Line: MCF7) [6]
Topotecan + Lapatinib DC2PFRZ Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + Lapatinib DCRZL02 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Topotecan + Lapatinib DCXVPTH Lapatinib Carcinoma (Cell Line: MDAMB436) [6]
Topotecan + Lapatinib DCHTJVO Lapatinib Carcinoma (Cell Line: MCF7) [6]
Topotecan + Lapatinib DC5IYT7 Lapatinib Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + Lapatinib DCHYCI4 Lapatinib Colon carcinoma (Cell Line: RKO) [6]
Topotecan + PMID28460551-Compound-2 DCFKOU7 PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + PMID28460551-Compound-2 DCDUA7M PMID28460551-Compound-2 Carcinoma (Cell Line: MCF7) [6]
Topotecan + PMID28460551-Compound-2 DCTJT6N PMID28460551-Compound-2 Colon carcinoma (Cell Line: RKO) [6]
Topotecan + PMID28460551-Compound-2 DCRUGXC PMID28460551-Compound-2 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Isoniazid DCM5AYI Isoniazid Carcinoma (Cell Line: MCF7) [6]
Topotecan + Arsenic trioxide DCCSSED Arsenic trioxide Carcinoma (Cell Line: MCF7) [6]
Topotecan + RTB101 DC5COY2 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + RTB101 DC4UEBS RTB101 Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + RTB101 DCAF5LU RTB101 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + RTB101 DCGVQFA RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Vemurafenib DCH0I2C Vemurafenib Carcinoma (Cell Line: MCF7) [6]
Topotecan + SCH-900776 DCWABDW SCH-900776 Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + SCH-900776 DC4E407 SCH-900776 Carcinoma (Cell Line: MDAMB436) [6]
Topotecan + SCH-900776 DC4AXUJ SCH-900776 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + SCH-900776 DCXVDME SCH-900776 Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + SCH-900776 DC0K9WT SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Plicamycin DCBV4UX Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Plicamycin DCXEPOI Plicamycin Carcinoma (Cell Line: RXF 393) [6]
Topotecan + Plicamycin DCWPAP7 Plicamycin Carcinoma (Cell Line: MCF7) [6]
Topotecan + Plicamycin DCJPO4J Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + Nilotinib DCW4NJU Nilotinib Carcinoma (Cell Line: MCF7) [6]
Topotecan + Triapine DCFQ8Q4 Triapine Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Triapine DCQ768P Triapine Carcinoma (Cell Line: MCF7) [6]
Topotecan + Topetecan DCT2YGY Topetecan Carcinoma (Cell Line: MCF7) [6]
Topotecan + Pralatrexate DCKLZH0 Pralatrexate Carcinoma (Cell Line: MCF7) [6]
Topotecan + SNX-2112 DCVP8UA SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + SNX-2112 DC2PHNM SNX-2112 Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + SNX-2112 DCG7HK6 SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Terameprocol DCB2JJN Terameprocol Carcinoma (Cell Line: MCF7) [6]
Topotecan + SCH 727965 DCYQDCC SCH 727965 Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + SCH 727965 DC6TAOE SCH 727965 Carcinoma (Cell Line: OV90) [6]
Topotecan + SCH 727965 DCLKC97 SCH 727965 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + SCH 727965 DCJZP37 SCH 727965 Carcinoma (Cell Line: MCF7) [6]
Topotecan + SCH 727965 DCBG3SN SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + SCH 727965 DCIRBI7 SCH 727965 Colon carcinoma (Cell Line: RKO) [6]
Topotecan + SCH 727965 DCMXFXM SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Erlotinib DCSYELD Erlotinib Breast carcinoma (Cell Line: KPL1) [6]
Topotecan + Erlotinib DCRBDG0 Erlotinib Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + Erlotinib DCRZ96R Erlotinib Carcinoma (Cell Line: EFM192B) [6]
Topotecan + Erlotinib DCEGDPR Erlotinib Carcinoma (Cell Line: MDAMB436) [6]
Topotecan + Erlotinib DCL6352 Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + Erlotinib DCGE7O7 Erlotinib Colon carcinoma (Cell Line: RKO) [6]
Topotecan + Ifosfamide DCXHHRF Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + Ifosfamide DCFU837 Ifosfamide Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + MK-5108 DC0B4DZ MK-5108 Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + MK-5108 DC0A5IB MK-5108 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + MK-5108 DCKXV7I MK-5108 Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + Bendamustine hydrochloride DCOMDCG Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + Letrozole DC4FWJL Letrozole Carcinoma (Cell Line: MCF7) [6]
Topotecan + Mitomycin DCPAHAH Mitomycin Carcinoma (Cell Line: RXF 393) [6]
Topotecan + Mitomycin DC79K4M Mitomycin Carcinoma (Cell Line: MCF7) [6]
Topotecan + Mitomycin DCSQN9W Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + SY-1425 DCAE7XG SY-1425 Carcinoma (Cell Line: MCF7) [6]
Topotecan + Arfolitixorin DC8GNGX Arfolitixorin Carcinoma (Cell Line: RXF 393) [6]
Topotecan + Arfolitixorin DC1X243 Arfolitixorin Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + Altretamine DCIPDNP Altretamine Carcinoma (Cell Line: MCF7) [6]
Topotecan + Ridaforolimus DC0ZEKI Ridaforolimus Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + Ridaforolimus DCDYH3F Ridaforolimus Carcinoma (Cell Line: EFM192B) [6]
Topotecan + Ridaforolimus DC7KLBQ Ridaforolimus Colon carcinoma (Cell Line: RKO) [6]
Topotecan + Ridaforolimus DCWF4HD Ridaforolimus Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + TEM DCF2LB2 TEM Carcinoma (Cell Line: MCF7) [6]
Topotecan + MK-4827 DCZMDHY MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + MK-4827 DCKOUS6 MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Topotecan + MK-4827 DCII00O MK-4827 Breast carcinoma (Cell Line: KPL1) [6]
Topotecan + MK-4827 DCZWDU0 MK-4827 Breast carcinoma (Cell Line: OCUBM) [6]
Topotecan + MK-4827 DCVIP3C MK-4827 Colon adenocarcinoma (Cell Line: LOVO) [6]
Topotecan + MK-4827 DCNVY2B MK-4827 Colon carcinoma (Cell Line: RKO) [6]
Topotecan + MK-4827 DC7MRWM MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + MK-4827 DCDPBVQ MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [6]
Topotecan + Imatinib DC10XIY Imatinib Carcinoma (Cell Line: MCF7) [6]
Topotecan + Bortezomib DC9EVWI Bortezomib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Bortezomib DCY4X66 Bortezomib Carcinoma (Cell Line: MCF7) [6]
Topotecan + Bortezomib DCKGA0N Bortezomib Colon carcinoma (Cell Line: RKO) [6]
Topotecan + GSK525762 DCL9W04 GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + GSK525762 DCOTE7T GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Topotecan + GSK525762 DC2DTSN GSK525762 Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + Cisplatin DCM7LBD Cisplatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Chlorambucil DC6UKR0 Chlorambucil Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Sorafenib DCFYBVP Sorafenib Breast carcinoma (Cell Line: ZR751) [6]
Topotecan + Sorafenib DC14B5H Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [6]
Topotecan + ER819762 DCEOX6C ER819762 Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + ER819762 DCH2QDH ER819762 Carcinoma (Cell Line: RXF 393) [6]
Topotecan + ER819762 DC7QZZY ER819762 Carcinoma (Cell Line: MCF7) [6]
Topotecan + MK-2206 DC1CO3X MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [6]
Topotecan + MK-2206 DCAL1IK MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [6]
Topotecan + MK-2206 DCDXGKV MK-2206 Carcinoma (Cell Line: EFM192B) [6]
Topotecan + MK-2206 DCLQH29 MK-2206 Colon carcinoma (Cell Line: RKO) [6]
Topotecan + Romidepsin DCG2PT3 Romidepsin Invasive ductal carcinoma (Cell Line: BT-549) [6]
Topotecan + Azacitidine DC6NEVT Azacitidine Carcinoma (Cell Line: MCF7) [6]
Topotecan + Pomalidomide DC4KCIJ Pomalidomide Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Topotecan + Pomalidomide DCWKEGY Pomalidomide Carcinoma (Cell Line: MCF7) [6]
Topotecan + Vinflunine DCSWPZC Vinflunine Carcinoma (Cell Line: MCF7) [6]
Topotecan + Vinflunine DCUQ6GX Vinflunine Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + Mercaptopurine DCB2ET0 Mercaptopurine Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Topotecan + Mepacrine DCMOS7M Mepacrine Carcinoma (Cell Line: MCF7) [6]
Topotecan + Fludarabine DCRXOFP Fludarabine Carcinoma (Cell Line: MCF7) [6]
Topotecan + FORMESTANE DCIBCIY FORMESTANE Carcinoma (Cell Line: MCF7) [6]
Topotecan + Digitoxin DCOUW8V Digitoxin Carcinoma (Cell Line: MCF7) [6]
Topotecan + Dasatinib DCWQF21 Dasatinib Carcinoma (Cell Line: MDAMB436) [6]
Topotecan + Dasatinib DCG14VB Dasatinib Colon carcinoma (Cell Line: RKO) [6]
Topotecan + Pentostatin DCLLXR2 Pentostatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Pentostatin DCNJOYT Pentostatin Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Pentostatin DCDCZCL Pentostatin Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Pentostatin DCF1X44 Pentostatin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Pentostatin DCUTNAU Pentostatin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Pentostatin DC9IP2A Pentostatin Glioma (Cell Line: SF-268) [7]
Topotecan + Pentostatin DCGYU9B Pentostatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Pentostatin DCGQPS1 Pentostatin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Picoplatin DCHBDZ4 Picoplatin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Picoplatin DCEPOLH Picoplatin Glioblastoma (Cell Line: SNB-75) [7]
Topotecan + Picoplatin DCAQEQW Picoplatin Glioma (Cell Line: SF-268) [7]
Topotecan + Picoplatin DCZN7EW Picoplatin Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Picoplatin DCUPNPP Picoplatin Melanoma (Cell Line: UACC-257) [7]
Topotecan + Picoplatin DCHQ8IZ Picoplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Fulvestrant DCDIGJD Fulvestrant Adenocarcinoma (Cell Line: DU-145) [7]
Topotecan + Fulvestrant DCYCKWD Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Fulvestrant DC5AP68 Fulvestrant Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Fulvestrant DC7LUGN Fulvestrant Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Fulvestrant DCW7HGT Fulvestrant Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Fulvestrant DCP4V87 Fulvestrant Glioma (Cell Line: SF-268) [7]
Topotecan + Fulvestrant DCGO9UQ Fulvestrant Melanoma (Cell Line: UACC-257) [7]
Topotecan + Fulvestrant DCAP53I Fulvestrant Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Fulvestrant DC266TN Fulvestrant Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Fulvestrant DCJNUDL Fulvestrant Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Fulvestrant DC1RAZQ Fulvestrant Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Fulvestrant DC35OJD Fulvestrant Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Fulvestrant DC2119F Fulvestrant Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Fulvestrant DCRDIFZ Fulvestrant Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Fulvestrant DCSPNZJ Fulvestrant Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Gefitinib DCMSXHM Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Clindamycin DCPK3JL Clindamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Paromomycin DC5A3IM Paromomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Aliskiren DC3ZOB0 Aliskiren Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + PD-0325901 DCT6GKK PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + PD-0325901 DCJQZ42 PD-0325901 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + PD-0325901 DC32I62 PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + PD-0325901 DCBPP1W PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + PD-0325901 DCFACZZ PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + PD-0325901 DC2PNT8 PD-0325901 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + PD-0325901 DCLQDZE PD-0325901 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + PD-0325901 DCN6XJ7 PD-0325901 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + PD-0325901 DCRV22A PD-0325901 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + PD-0325901 DCQAYUQ PD-0325901 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + PD-0325901 DCOFR51 PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + PD-0325901 DC5RN2I PD-0325901 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + PD-0325901 DCKTDYR PD-0325901 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + PD-0325901 DCELR9H PD-0325901 Malignant melanoma (Cell Line: A375) [7]
Topotecan + PD-0325901 DCTYW79 PD-0325901 Malignant melanoma (Cell Line: HT144) [7]
Topotecan + PD-0325901 DCO69YY PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [7]
Topotecan + PD-0325901 DCZ59ZJ PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + PD-0325901 DCJY6CJ PD-0325901 Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + PD-0325901 DCELTWO PD-0325901 Mesothelioma (Cell Line: MSTO) [7]
Topotecan + PD-0325901 DC1GPD7 PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [7]
Topotecan + PD-0325901 DCBQYW1 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + PD-0325901 DC4XMU3 PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + PD-0325901 DCO3BOQ PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [7]
Topotecan + PD-0325901 DCDPZM0 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + Hepzato DCX9JW2 Hepzato Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Hepzato DC6DFEF Hepzato Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Hepzato DC7H56D Hepzato Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Hepzato DCNEHVZ Hepzato Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Hepzato DC25LNG Hepzato Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Citalopram DCXSNH6 Citalopram Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Ixabepilone DCDZ77D Ixabepilone Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Ixabepilone DC0QH2K Ixabepilone Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Ixabepilone DCHI5BJ Ixabepilone Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Ixabepilone DCZLZNS Ixabepilone Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Ixabepilone DCPLZSI Ixabepilone Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Ixabepilone DC32JCJ Ixabepilone Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Ixabepilone DCU2CLV Ixabepilone Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Ixabepilone DCF8YDG Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Ixabepilone DCCDE0U Ixabepilone High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Topotecan + Ixabepilone DCFBBKQ Ixabepilone Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Ixabepilone DC6XIC2 Ixabepilone Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Ixabepilone DC7WY5T Ixabepilone Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Ixabepilone DCROCG9 Ixabepilone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Ixabepilone DCJ614K Ixabepilone Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Ixabepilone DCC017O Ixabepilone Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Ixabepilone DC2IQIG Ixabepilone Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Crotamiton DCF6SEY Crotamiton Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Dactinomycin DCCBT2M Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + Dactinomycin DC831ZM Dactinomycin Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + Dactinomycin DCUQ0N1 Dactinomycin Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Dactinomycin DC0AM0X Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Dactinomycin DCTVSQ2 Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Dactinomycin DCKADZ1 Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Dactinomycin DCZ5RAO Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Dactinomycin DCJ17RG Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Dactinomycin DCRYZ7J Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Dactinomycin DCU1A8D Dactinomycin Glioma (Cell Line: SF-268) [7]
Topotecan + Dactinomycin DCMWQA4 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Topotecan + Dactinomycin DCMD550 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Topotecan + Dactinomycin DCYL17A Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Topotecan + Dactinomycin DCFHSCL Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Topotecan + Dactinomycin DC8U0Q0 Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [7]
Topotecan + Dactinomycin DCZ8HID Dactinomycin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Dactinomycin DCDXZTZ Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Dactinomycin DCJ0SOA Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Dactinomycin DC0M8YU Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Topotecan + Dactinomycin DCAZFVP Dactinomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Dactinomycin DCC5PAB Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Dactinomycin DC4LZ7Z Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Dactinomycin DCJB1IG Dactinomycin Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + DFN-15 DCI3FBW DFN-15 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + DFN-15 DC1U9BW DFN-15 Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + DFN-15 DCQB8NQ DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + DFN-15 DCR9AM2 DFN-15 Melanoma (Cell Line: UACC-257) [7]
Topotecan + DFN-15 DCMHL31 DFN-15 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + DFN-15 DCY4GRK DFN-15 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + DFN-15 DC14MIJ DFN-15 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + DFN-15 DCRTPF4 DFN-15 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + DFN-15 DCNCZFO DFN-15 Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + DFN-15 DC51OL4 DFN-15 Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Lapatinib DCQ3W5L Lapatinib Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + Lapatinib DCJPHFZ Lapatinib Adenocarcinoma (Cell Line: A427) [7]
Topotecan + Lapatinib DCQVINH Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + Lapatinib DCS485X Lapatinib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Lapatinib DCGB6G4 Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + Lapatinib DCLJRLI Lapatinib Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + Lapatinib DCXVRJC Lapatinib Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + Lapatinib DC8X9XO Lapatinib Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Lapatinib DCT6ZP7 Lapatinib Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Lapatinib DCCHMAX Lapatinib Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Lapatinib DC7EZMP Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Lapatinib DCVUTTJ Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Lapatinib DCUCO7M Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + Lapatinib DC6DQRB Lapatinib Germ cell tumour (Cell Line: PA1) [7]
Topotecan + Lapatinib DCJQZTD Lapatinib Glioma (Cell Line: SF-268) [7]
Topotecan + Lapatinib DC1O210 Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Topotecan + Lapatinib DCYOPYQ Lapatinib Malignant melanoma (Cell Line: RPMI7951) [7]
Topotecan + Lapatinib DCEGB43 Lapatinib Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + Lapatinib DCJ7NF1 Lapatinib Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + Lapatinib DCYI29S Lapatinib Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Lapatinib DCGJXJA Lapatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Lapatinib DCBEKBF Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Lapatinib DC4MBOD Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Lapatinib DCXH2KT Lapatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Lapatinib DCL5U9T Lapatinib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Lapatinib DCMQJ51 Lapatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Lapatinib DCQPSNL Lapatinib Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + Lapatinib DCQS5F5 Lapatinib Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Terazosin DCPM070 Terazosin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Chlorphenesin DCA3ET4 Chlorphenesin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + MK-1775 DCGY7GB MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + MK-1775 DC7QUPF MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + MK-1775 DCJ8H74 MK-1775 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + MK-1775 DCC5MCG MK-1775 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + MK-1775 DCJZG2O MK-1775 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + MK-1775 DCU46KT MK-1775 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + MK-1775 DCU12WP MK-1775 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + MK-1775 DC1LCTT MK-1775 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + MK-1775 DC3H1AG MK-1775 Malignant melanoma (Cell Line: A375) [7]
Topotecan + MK-1775 DCMXLK1 MK-1775 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + MK-1775 DCP5151 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + MK-1775 DC4R94Q MK-1775 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + PMID28460551-Compound-2 DCBZA6T PMID28460551-Compound-2 Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + PMID28460551-Compound-2 DC5UB29 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + PMID28460551-Compound-2 DCAK7U2 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [7]
Topotecan + PMID28460551-Compound-2 DCR3FXW PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + PMID28460551-Compound-2 DCP3YEZ PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + PMID28460551-Compound-2 DC8IDF9 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + PMID28460551-Compound-2 DCP60ZP PMID28460551-Compound-2 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + PMID28460551-Compound-2 DCG4621 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + PMID28460551-Compound-2 DC4SPUR PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + PMID28460551-Compound-2 DCS6M66 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + PMID28460551-Compound-2 DCRJ8NN PMID28460551-Compound-2 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + PMID28460551-Compound-2 DCRFWGZ PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + PMID28460551-Compound-2 DCCW4QX PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + PMID28460551-Compound-2 DC9PUM8 PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + PMID28460551-Compound-2 DCY9SX3 PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + PMID28460551-Compound-2 DCR4S4G PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + PMID28460551-Compound-2 DC6TPTV PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + PMID28460551-Compound-2 DC7QPVW PMID28460551-Compound-2 Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + PMID28460551-Compound-2 DCSI60C PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + PMID28460551-Compound-2 DC2DIRD PMID28460551-Compound-2 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + PMID28460551-Compound-2 DCJEDEP PMID28460551-Compound-2 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + PMID28460551-Compound-2 DC2N8ZF PMID28460551-Compound-2 Malignant melanoma (Cell Line: A375) [7]
Topotecan + PMID28460551-Compound-2 DCITTM5 PMID28460551-Compound-2 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + PMID28460551-Compound-2 DCFFO3D PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + PMID28460551-Compound-2 DCB1JOA PMID28460551-Compound-2 Melanoma (Cell Line: MALME-3M) [7]
Topotecan + PMID28460551-Compound-2 DC7X16O PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [7]
Topotecan + PMID28460551-Compound-2 DC2M8Z3 PMID28460551-Compound-2 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + PMID28460551-Compound-2 DCNNVRC PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + PMID28460551-Compound-2 DCFQ1GT PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [7]
Topotecan + PMID28460551-Compound-2 DCO9I00 PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + PMID28460551-Compound-2 DC91P8V PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + PMID28460551-Compound-2 DCXX779 PMID28460551-Compound-2 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + PMID28460551-Compound-2 DC7R11S PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + PMID28460551-Compound-2 DCEXI22 PMID28460551-Compound-2 Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Crizotinib DCP3OQ3 Crizotinib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Crizotinib DCMWSRY Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Crizotinib DC55KFV Crizotinib Glioma (Cell Line: SF-268) [7]
Topotecan + Crizotinib DC5GNKS Crizotinib Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Crizotinib DCXV3S8 Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Crizotinib DCJERAI Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Crizotinib DC520G9 Crizotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Crizotinib DCBNEED Crizotinib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Crizotinib DC0YWBQ Crizotinib Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Crizotinib DCTJEDG Crizotinib Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Cyclophosphamide DCBIC9K Cyclophosphamide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + LIAROZOLE DC16Q6Q LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + LIAROZOLE DCHX2QY LIAROZOLE Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + LIAROZOLE DCKX3TO LIAROZOLE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + LIAROZOLE DCNS9I4 LIAROZOLE Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + LIAROZOLE DCMP3Y4 LIAROZOLE Glioma (Cell Line: SF-268) [7]
Topotecan + LIAROZOLE DC7ZSWT LIAROZOLE Melanoma (Cell Line: MALME-3M) [7]
Topotecan + LIAROZOLE DC8BLS3 LIAROZOLE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + LIAROZOLE DCGDFU2 LIAROZOLE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + LIAROZOLE DCPC5NE LIAROZOLE Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + LIAROZOLE DCTV79K LIAROZOLE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Methotrexate DCKYX82 Methotrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Topotecan + Methotrexate DCC7GEC Methotrexate Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Methotrexate DCC8052 Methotrexate Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Isoniazid DCW7EIQ Isoniazid Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Isoniazid DCR0MEM Isoniazid Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Isoniazid DC7LO2F Isoniazid Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Isoniazid DC1T0M7 Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Isoniazid DCG5BHP Isoniazid Glioblastoma (Cell Line: SNB-75) [7]
Topotecan + Isoniazid DCSL5IX Isoniazid Glioma (Cell Line: SF-268) [7]
Topotecan + Isoniazid DCS0UWV Isoniazid Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Isoniazid DCM67IG Isoniazid Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Isoniazid DC92PKD Isoniazid Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Isoniazid DC9925I Isoniazid Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Isoniazid DC3Q2KW Isoniazid Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Arsenic trioxide DCT6P7N Arsenic trioxide Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Arsenic trioxide DC4ZWNX Arsenic trioxide Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Arsenic trioxide DCTLM1L Arsenic trioxide Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Arsenic trioxide DCWPW4N Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Arsenic trioxide DC4PRS5 Arsenic trioxide Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Arsenic trioxide DCGTF42 Arsenic trioxide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Arsenic trioxide DCGAFHX Arsenic trioxide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Arsenic trioxide DCILY7K Arsenic trioxide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Arsenic trioxide DC54I6G Arsenic trioxide Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Arsenic trioxide DC36Y3O Arsenic trioxide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Arsenic trioxide DC02J4O Arsenic trioxide Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + RTB101 DCU7Y3I RTB101 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + RTB101 DCIEMLA RTB101 Adenocarcinoma (Cell Line: NCIH1650) [7]
Topotecan + RTB101 DCJI2P2 RTB101 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + RTB101 DCQH0CC RTB101 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + RTB101 DCWCK25 RTB101 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + RTB101 DC79END RTB101 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + RTB101 DCLKIEL RTB101 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + RTB101 DCBXQ1R RTB101 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + RTB101 DC2OV98 RTB101 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + RTB101 DC6FRQK RTB101 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + RTB101 DC9E021 RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + RTB101 DCXRFYS RTB101 Malignant melanoma (Cell Line: A375) [7]
Topotecan + RTB101 DCYINVY RTB101 Malignant melanoma (Cell Line: HT144) [7]
Topotecan + RTB101 DCON7DV RTB101 Malignant melanoma (Cell Line: RPMI7951) [7]
Topotecan + RTB101 DC9A2G5 RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + RTB101 DCG7LEP RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + RTB101 DCF9BZL RTB101 Prostate carcinoma (Cell Line: LNCAP) [7]
Topotecan + Vemurafenib DCRKMG5 Vemurafenib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Vemurafenib DCLHUUJ Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Vemurafenib DCO8824 Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Vemurafenib DC6X39I Vemurafenib Glioma (Cell Line: SF-268) [7]
Topotecan + Vemurafenib DCWNGKC Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Vemurafenib DCIJ68L Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Vemurafenib DCEWLT9 Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Vemurafenib DC0I5VV Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Vemurafenib DCOOYO7 Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Vemurafenib DC70Q7F Vemurafenib Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + SCH-900776 DCFP594 SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + SCH-900776 DCC7FHS SCH-900776 Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + SCH-900776 DCAMOSF SCH-900776 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + SCH-900776 DCI3SHT SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + SCH-900776 DCLSTM8 SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + SCH-900776 DCBW31M SCH-900776 Adenocarcinoma (Cell Line: NCIH1650) [7]
Topotecan + SCH-900776 DCLR5OW SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + SCH-900776 DC7M74Y SCH-900776 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + SCH-900776 DC922SZ SCH-900776 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + SCH-900776 DCETFRA SCH-900776 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + SCH-900776 DCTUVI2 SCH-900776 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + SCH-900776 DCVZGGG SCH-900776 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + SCH-900776 DC6BGOC SCH-900776 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + SCH-900776 DCS4JPW SCH-900776 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + SCH-900776 DCRYU0H SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + SCH-900776 DC1UO09 SCH-900776 Malignant melanoma (Cell Line: A375) [7]
Topotecan + SCH-900776 DCM3L9F SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [7]
Topotecan + SCH-900776 DCV0ROY SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [7]
Topotecan + SCH-900776 DCZYAM4 SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + SCH-900776 DCZM1E2 SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Sivelestat DC8P7R2 Sivelestat Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Plicamycin DCKL2TE Plicamycin Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Plicamycin DCZFFS0 Plicamycin Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Plicamycin DCB69F5 Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Plicamycin DC27LN9 Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Plicamycin DCXTAFG Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Plicamycin DCRMB17 Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Plicamycin DC2P06D Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Plicamycin DCMP9R4 Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Plicamycin DC6FXG1 Plicamycin Glioblastoma (Cell Line: SNB-75) [7]
Topotecan + Plicamycin DC0TOI6 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Topotecan + Plicamycin DCOW38N Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Topotecan + Plicamycin DCD8ZT7 Plicamycin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Plicamycin DC72SEM Plicamycin Melanoma (Cell Line: SK-MEL-2) [7]
Topotecan + Plicamycin DCEHBHL Plicamycin Melanoma (Cell Line: UACC-257) [7]
Topotecan + Plicamycin DCJWGDK Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Plicamycin DCAAJDR Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Plicamycin DCUKVM3 Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Plicamycin DCVN2FV Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Plicamycin DCBXF00 Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Plicamycin DCEFZUE Plicamycin Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Nilotinib DCQPFO9 Nilotinib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Nilotinib DCCZCSR Nilotinib Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Nilotinib DC4Q9SZ Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Nilotinib DC2II91 Nilotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Nilotinib DCMJ2AB Nilotinib Glioma (Cell Line: SF-268) [7]
Topotecan + Nilotinib DCOXFIQ Nilotinib Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Nilotinib DCQ3D78 Nilotinib Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Nilotinib DCEU2HE Nilotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Nilotinib DCGHFAU Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Nilotinib DCAL4DI Nilotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Nilotinib DCXA3WI Nilotinib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Nilotinib DCYI8YZ Nilotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Nilotinib DCT4GC6 Nilotinib Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Ramelteon DCG1LVW Ramelteon Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Triapine DCUBVJ8 Triapine Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Triapine DCPK6Z9 Triapine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Triapine DCDDHAM Triapine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Triapine DCQ8BZU Triapine Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Triapine DC56P2N Triapine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Acitretin DC09UEV Acitretin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Pepstatin DCGX9FX Pepstatin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + 10-hydroxycamptothecin DCHXXJQ 10-hydroxycamptothecin Adenocarcinoma (Cell Line: A549) [7]
Topotecan + 10-hydroxycamptothecin DCBKJ88 10-hydroxycamptothecin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + 10-hydroxycamptothecin DCBN5IP 10-hydroxycamptothecin Melanoma (Cell Line: UACC-257) [7]
Topotecan + 10-hydroxycamptothecin DCLMILN 10-hydroxycamptothecin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + 10-hydroxycamptothecin DCLNW4U 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + 10-hydroxycamptothecin DCKY0LC 10-hydroxycamptothecin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + 10-hydroxycamptothecin DCE2M5F 10-hydroxycamptothecin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Topetecan DCCYOOW Topetecan Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Topetecan DCIF5CT Topetecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Topetecan DCY5XZM Topetecan Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Topetecan DCQP5WK Topetecan Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Topetecan DCSFE3Z Topetecan Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Topetecan DC6T63F Topetecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Topetecan DCLDTZS Topetecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Topetecan DCKAVHX Topetecan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Topetecan DCT4JUC Topetecan Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Topetecan DCXPEK6 Topetecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Pralatrexate DCWMOF2 Pralatrexate Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Pralatrexate DC1Y31T Pralatrexate Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Pralatrexate DCFLFBQ Pralatrexate Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Pralatrexate DCXDWYI Pralatrexate Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Pralatrexate DC2BKCK Pralatrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Topotecan + Pralatrexate DCN8X2Z Pralatrexate Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Pralatrexate DCU4XMG Pralatrexate Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Pralatrexate DCZ0RPR Pralatrexate Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Pralatrexate DCEKO2O Pralatrexate Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Pralatrexate DCF6CEH Pralatrexate Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Pralatrexate DC91QQO Pralatrexate Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + SNX-2112 DCBEXH8 SNX-2112 Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + SNX-2112 DCLW2DT SNX-2112 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + SNX-2112 DCMOQ2Z SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + SNX-2112 DCNTDK3 SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + SNX-2112 DCN2AWX SNX-2112 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + SNX-2112 DCUSSC4 SNX-2112 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + SNX-2112 DC1WGFU SNX-2112 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + SNX-2112 DCYLVEJ SNX-2112 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + SNX-2112 DCKS4DS SNX-2112 Malignant melanoma (Cell Line: A375) [7]
Topotecan + SNX-2112 DCGVBG2 SNX-2112 Malignant melanoma (Cell Line: HT144) [7]
Topotecan + SNX-2112 DC9WYKP SNX-2112 Mesothelioma (Cell Line: MSTO) [7]
Topotecan + SNX-2112 DCCR2VW SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + SNX-2112 DC2S58Q SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + SNX-2112 DC0GNP4 SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [7]
Topotecan + SNX-2112 DCCVR56 SNX-2112 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + Methylergonovine DCWXDA2 Methylergonovine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Palonosetron DCB8YN5 Palonosetron Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + BHV-0223 DCJ2L5I BHV-0223 Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Buspirone DC3FM9S Buspirone Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Metyrosine DCZWRHZ Metyrosine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Efavirenz DCFU6CZ Efavirenz Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Testosterone cypionate DCNMUVB Testosterone cypionate Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Terameprocol DCRX4AG Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Terameprocol DC1B4DJ Terameprocol Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Terameprocol DCU7FJ5 Terameprocol Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Terameprocol DC7KF4D Terameprocol Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Terameprocol DCHH52G Terameprocol Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Terameprocol DCEN9PL Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Terameprocol DCZRX3H Terameprocol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Terameprocol DCUYPYL Terameprocol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Terameprocol DC1MC3E Terameprocol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Terameprocol DCFL2XL Terameprocol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Guanfacine DCO606O Guanfacine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + SCH 727965 DC2ZJGT SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + SCH 727965 DCO87VX SCH 727965 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + SCH 727965 DCAHS37 SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [7]
Topotecan + SCH 727965 DCF61JD SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + SCH 727965 DCX5CN2 SCH 727965 Adenocarcinoma (Cell Line: A549) [7]
Topotecan + SCH 727965 DCJZT3L SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + SCH 727965 DC7K6DG SCH 727965 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + SCH 727965 DCY7CXC SCH 727965 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + SCH 727965 DCBMX96 SCH 727965 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + SCH 727965 DCRS6XV SCH 727965 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + SCH 727965 DCBOX84 SCH 727965 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + SCH 727965 DCQQV9Z SCH 727965 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + SCH 727965 DCLLM87 SCH 727965 Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + SCH 727965 DCXH2F4 SCH 727965 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + SCH 727965 DC5NJGZ SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + SCH 727965 DC8MIMB SCH 727965 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + SCH 727965 DC7ASKH SCH 727965 Glioma (Cell Line: SF-268) [7]
Topotecan + SCH 727965 DC1KS14 SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + SCH 727965 DCOCEWI SCH 727965 Malignant melanoma (Cell Line: A375) [7]
Topotecan + SCH 727965 DCH5G31 SCH 727965 Malignant melanoma (Cell Line: HT144) [7]
Topotecan + SCH 727965 DCGG4XI SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [7]
Topotecan + SCH 727965 DCV2M07 SCH 727965 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + SCH 727965 DCY69IC SCH 727965 Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + SCH 727965 DC5PDRH SCH 727965 Melanoma (Cell Line: MALME-3M) [7]
Topotecan + SCH 727965 DC5VN9Q SCH 727965 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + SCH 727965 DC26JD8 SCH 727965 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + SCH 727965 DCQ4J2E SCH 727965 Non small cell carcinoma (Cell Line: SKMES1) [7]
Topotecan + SCH 727965 DCSKVHN SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + SCH 727965 DCP944H SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + SCH 727965 DCVC1DL SCH 727965 Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + SCH 727965 DCPXDTD SCH 727965 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + SCH 727965 DCELSAL SCH 727965 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + SCH 727965 DC85ZZJ SCH 727965 Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Erlotinib DC8O778 Erlotinib Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + Erlotinib DCGBFH4 Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + Erlotinib DCSMBDL Erlotinib Adenocarcinoma (Cell Line: A427) [7]
Topotecan + Erlotinib DCZPFC0 Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + Erlotinib DCF8G91 Erlotinib Adenocarcinoma (Cell Line: NCIH23) [7]
Topotecan + Erlotinib DC0FIVH Erlotinib Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + Erlotinib DCPEV27 Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + Erlotinib DC8CQPP Erlotinib Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + Erlotinib DC29TC4 Erlotinib Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + Erlotinib DCFNQLC Erlotinib Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Erlotinib DCDWI6U Erlotinib Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Erlotinib DCI1ZUN Erlotinib Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Erlotinib DCO31CG Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + Erlotinib DC8DUJ4 Erlotinib Germ cell tumour (Cell Line: PA1) [7]
Topotecan + Erlotinib DCX3PDX Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + Erlotinib DCLCASU Erlotinib Malignant melanoma (Cell Line: A375) [7]
Topotecan + Erlotinib DC54PVX Erlotinib Malignant melanoma (Cell Line: HT144) [7]
Topotecan + Erlotinib DC6JX2H Erlotinib Malignant melanoma (Cell Line: RPMI7951) [7]
Topotecan + Erlotinib DCJKQCL Erlotinib Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + Erlotinib DCDM74B Erlotinib Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + Erlotinib DCOCYTO Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Erlotinib DC0D2P3 Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Erlotinib DCZVHNJ Erlotinib Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + Ifosfamide DCZK8SG Ifosfamide Glioma (Cell Line: SF-268) [7]
Topotecan + Docetaxel DCHRY14 Docetaxel Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Docetaxel DCCB7RC Docetaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Docetaxel DCSYJLS Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Raloxifene DC3QFJ1 Raloxifene Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Pazopanib DCLJ83O Pazopanib Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + MK-5108 DCENTX1 MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + MK-5108 DCC8RSG MK-5108 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + MK-5108 DCN1HHM MK-5108 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + MK-5108 DCT4ZHB MK-5108 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + MK-5108 DCCLYBR MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + MK-5108 DC13C5B MK-5108 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + MK-5108 DCDAJE5 MK-5108 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + MK-5108 DC4F7K9 MK-5108 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + MK-5108 DCVI8L7 MK-5108 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + MK-5108 DC7MB92 MK-5108 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + MK-5108 DCQTLT8 MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + MK-5108 DCX08VO MK-5108 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + MK-5108 DC7UDJZ MK-5108 Malignant melanoma (Cell Line: A375) [7]
Topotecan + MK-5108 DCW552U MK-5108 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + MK-5108 DCEO6HT MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + MK-5108 DCRVT2C MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Bendamustine hydrochloride DCZ2LET Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Bendamustine hydrochloride DCLE8SJ Bendamustine hydrochloride Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Bendamustine hydrochloride DC5GR4B Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Bendamustine hydrochloride DCAW70D Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Bendamustine hydrochloride DCN8KK1 Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Bendamustine hydrochloride DCWGMSR Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Bendamustine hydrochloride DCVIIS9 Bendamustine hydrochloride Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Bendamustine hydrochloride DCS40FU Bendamustine hydrochloride Glioma (Cell Line: SF-268) [7]
Topotecan + Bendamustine hydrochloride DC0HVFL Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Topotecan + Bendamustine hydrochloride DCVE8UK Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Bendamustine hydrochloride DCK13UJ Bendamustine hydrochloride Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Bendamustine hydrochloride DC4NV8E Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Bendamustine hydrochloride DCQWJH8 Bendamustine hydrochloride Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Bendamustine hydrochloride DCUR3GY Bendamustine hydrochloride Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Bendamustine hydrochloride DC64CTI Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Bendamustine hydrochloride DCOX7RI Bendamustine hydrochloride Renal cell carcinoma (Cell Line: UO-31) [7]
Topotecan + Fluspirilene DCNVYW9 Fluspirilene Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + VR-776 DCR7V6R VR-776 Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Ciprofibrate DC058WK Ciprofibrate Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Mecamylamine DC5YI7S Mecamylamine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Sirolimus DCM6UL6 Sirolimus Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Sirolimus DCYKTGD Sirolimus Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Sirolimus DCWP6H1 Sirolimus Glioma (Cell Line: SF-268) [7]
Topotecan + Sirolimus DCRRPLX Sirolimus Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + PHA-739358 DCXKQZQ PHA-739358 Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Letrozole DCK252G Letrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Letrozole DCMPKGZ Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Letrozole DCGL4CI Letrozole Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Letrozole DCOUP7U Letrozole Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Letrozole DCZPR1R Letrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Letrozole DCZEQHB Letrozole Melanoma (Cell Line: UACC-257) [7]
Topotecan + Letrozole DCNLQVD Letrozole Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Letrozole DC3SIE5 Letrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Letrozole DCVDM0H Letrozole Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Letrozole DCEX7IM Letrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Letrozole DCHXD9D Letrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Letrozole DCXYS49 Letrozole Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Mitomycin DC1H5OJ Mitomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Mitomycin DCJQCHB Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Mitomycin DCFQ85Z Mitomycin Glioma (Cell Line: SF-268) [7]
Topotecan + Mitomycin DCVA7OL Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Topotecan + Mitomycin DC0AN9H Mitomycin Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Mitomycin DCRXU7P Mitomycin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Mitomycin DCHQ2ZU Mitomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Mitomycin DCGTBLB Mitomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Mitomycin DCS46OW Mitomycin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Mitomycin DC1W037 Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + SY-1425 DCGVY8E SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + SY-1425 DCB5EJM SY-1425 Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + SY-1425 DCNFOTE SY-1425 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + SY-1425 DCSERC3 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + SY-1425 DCCOIK3 SY-1425 Glioma (Cell Line: SF-268) [7]
Topotecan + SY-1425 DCC740M SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Topotecan + SY-1425 DCF9089 SY-1425 Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + SY-1425 DCIKAMH SY-1425 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + SY-1425 DCFMJ7K SY-1425 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + SY-1425 DCM7VUG SY-1425 Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Topotecan + SY-1425 DC5ZJES SY-1425 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + SY-1425 DCF5OWL SY-1425 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + SY-1425 DCJ614X SY-1425 Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Diphenidol DC4JXH6 Diphenidol Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Tolazoline DCXIDK5 Tolazoline Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Vincristine DC3KEPV Vincristine Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Vincristine DCMQS1X Vincristine Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Vincristine DC8SWI7 Vincristine Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Vincristine DCURQ9A Vincristine Anaplastic large cell lymphoma (Cell Line: SR) [7]
Topotecan + Vincristine DCVU5WW Vincristine Clear cell renal cell carcinoma (Cell Line: A498) [7]
Topotecan + Vincristine DCLO8Q7 Vincristine Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Vincristine DC9J98Q Vincristine Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Sulfapyridine DC9T1VM Sulfapyridine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Arfolitixorin DCRCYKT Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Arfolitixorin DC2I09O Arfolitixorin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Arfolitixorin DCZDKN5 Arfolitixorin Glioma (Cell Line: SF-268) [7]
Topotecan + Arfolitixorin DCP1NN9 Arfolitixorin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Topotecan + Arfolitixorin DCNCJ2N Arfolitixorin Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Arfolitixorin DC8I9Z3 Arfolitixorin Melanoma (Cell Line: UACC-257) [7]
Topotecan + Arfolitixorin DCTV704 Arfolitixorin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Arfolitixorin DCFY4BF Arfolitixorin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Arfolitixorin DCEKHT3 Arfolitixorin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Arfolitixorin DCINZO1 Arfolitixorin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Arfolitixorin DCLFTRL Arfolitixorin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Triflupromazine DCXARTJ Triflupromazine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Lubiprostone DCH5AQJ Lubiprostone Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Altretamine DC0TDQD Altretamine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Altretamine DCS66Z7 Altretamine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Altretamine DCY80MR Altretamine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Tiagabine DCEKZLV Tiagabine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Diazoxide DCXK01Z Diazoxide Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Ridaforolimus DCGPGL1 Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [7]
Topotecan + Ridaforolimus DCMSXNH Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + Ridaforolimus DCOP16M Ridaforolimus Adenocarcinoma (Cell Line: NCIH23) [7]
Topotecan + Ridaforolimus DC06EGR Ridaforolimus Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + Ridaforolimus DCUALSA Ridaforolimus Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + Ridaforolimus DCBYXSE Ridaforolimus Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + Ridaforolimus DC5MA5R Ridaforolimus Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Ridaforolimus DCS449Y Ridaforolimus Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Ridaforolimus DCWE12J Ridaforolimus Germ cell tumour (Cell Line: PA1) [7]
Topotecan + Ridaforolimus DCHHSG7 Ridaforolimus Mesothelioma (Cell Line: MSTO) [7]
Topotecan + Ridaforolimus DCXOK60 Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Ridaforolimus DCICO6J Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [7]
Topotecan + TEM DCEJYM4 TEM Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + TEM DCZ1FQP TEM Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + TEM DC271N6 TEM Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + TEM DCPCRJ2 TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + TEM DCM6HJV TEM Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + TEM DCIX18S TEM Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + TEM DCYJOD3 TEM Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + TEM DC9ZREI TEM Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + TEM DCBO1EW TEM Melanoma (Cell Line: MALME-3M) [7]
Topotecan + TEM DCVPMNS TEM Melanoma (Cell Line: UACC-257) [7]
Topotecan + TEM DCOHWM3 TEM Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + TEM DCHRHF3 TEM Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + TEM DCL76XU TEM Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + TEM DC7HDPD TEM Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + TEM DCR0EXB TEM Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + TEM DCIWFSG TEM Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + TEM DCT0VAV TEM Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Benserazide DCSI8BZ Benserazide Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + JNK-IN-8 DC6HTVH JNK-IN-8 Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + MK-4827 DCHRF8K MK-4827 Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + MK-4827 DC70YC5 MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + MK-4827 DCV6HWC MK-4827 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + MK-4827 DCA3XCY MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + MK-4827 DC1XNHI MK-4827 Adenocarcinoma (Cell Line: NCIH23) [7]
Topotecan + MK-4827 DCL62JN MK-4827 Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + MK-4827 DCM6JTJ MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + MK-4827 DCANWEH MK-4827 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + MK-4827 DCZHVBI MK-4827 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + MK-4827 DCMY6O1 MK-4827 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + MK-4827 DCC0Y4E MK-4827 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + MK-4827 DC9NSG0 MK-4827 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + MK-4827 DCDELN2 MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + MK-4827 DCUJ0HD MK-4827 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + MK-4827 DCBYEW7 MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + MK-4827 DCRJ694 MK-4827 Malignant melanoma (Cell Line: A375) [7]
Topotecan + MK-4827 DCEXYGY MK-4827 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + MK-4827 DCR4J4O MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [7]
Topotecan + MK-4827 DCZ1MSP MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + MK-4827 DCC4PTS MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + MK-4827 DCEV2HU MK-4827 Prostate carcinoma (Cell Line: LNCAP) [7]
Topotecan + MK-4827 DCYF19E MK-4827 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + Idarubicin DCSWMTA Idarubicin Adenocarcinoma (Cell Line: A427) [7]
Topotecan + Idarubicin DCVWMMD Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + Idarubicin DCV9NZM Idarubicin Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Idarubicin DCAY5RM Idarubicin Glioblastoma? (Cell Line: T98G) [7]
Topotecan + Idarubicin DCUHP8W Idarubicin Glioma (Cell Line: SF-268) [7]
Topotecan + Idarubicin DCAKMR3 Idarubicin Melanoma (Cell Line: UACC-257) [7]
Topotecan + Idarubicin DCPDYKV Idarubicin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Idarubicin DCOSH7A Idarubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Idarubicin DCFCZ6D Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Idarubicin DCJY2PX Idarubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Idarubicin DCHUY55 Idarubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Imatinib DCIMDQQ Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Imatinib DCMJTKE Imatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Imatinib DC17H1X Imatinib Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Imatinib DCWM19T Imatinib Glioma (Cell Line: SF-268) [7]
Topotecan + Imatinib DCQS371 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Topotecan + Imatinib DC8LHHK Imatinib Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Imatinib DC1XXZT Imatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Imatinib DCGKHKI Imatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Imatinib DCNKQ3K Imatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Imatinib DC44Z5Y Imatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Imatinib DC0JQZK Imatinib Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Bleomycin DCAL5YJ Bleomycin Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Bleomycin DCC279J Bleomycin Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Bleomycin DCJPGGH Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [7]
Topotecan + Bleomycin DCTGTJQ Bleomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Bleomycin DCU3EH0 Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [7]
Topotecan + Bleomycin DCPC055 Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Bleomycin DCN13MU Bleomycin Melanoma (Cell Line: SK-MEL-2) [7]
Topotecan + Bleomycin DC9PVJH Bleomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Bleomycin DC333OW Bleomycin Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Topotecan + Pramipexole DC0E071 Pramipexole Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Bortezomib DCY580X Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + Bortezomib DCQVTOR Bortezomib Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + Bortezomib DCF95N8 Bortezomib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Bortezomib DCU231E Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + Bortezomib DCVOLY2 Bortezomib Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + Bortezomib DCTREM8 Bortezomib Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Bortezomib DC7F2JG Bortezomib Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Bortezomib DC5P6PH Bortezomib Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Bortezomib DC9695D Bortezomib Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Bortezomib DCXC3DR Bortezomib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Bortezomib DCV009E Bortezomib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Bortezomib DCIE4R7 Bortezomib Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Bortezomib DCI6I4M Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + Bortezomib DCLSJ1J Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + Bortezomib DCYFPNC Bortezomib Mesothelioma (Cell Line: MSTO) [7]
Topotecan + Bortezomib DCB8ZSS Bortezomib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Bortezomib DCKCUV2 Bortezomib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Bortezomib DCMF6XI Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Bortezomib DCM50XU Bortezomib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Bortezomib DCH6QET Bortezomib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Bortezomib DCCC5TI Bortezomib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Bortezomib DCPTDDF Bortezomib Prostate carcinoma (Cell Line: LNCAP) [7]
Topotecan + Bortezomib DC5JVGV Bortezomib Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Ethinyl estradiol DCJVT2J Ethinyl estradiol Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Mesalazine DCM6913 Mesalazine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Valrubicin DCM1JXN Valrubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Valrubicin DCK1YSB Valrubicin Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Valrubicin DCO2L51 Valrubicin Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Valrubicin DC3Q6T6 Valrubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Valrubicin DCOGUIX Valrubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Valrubicin DCNVAAT Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Valrubicin DC7INYL Valrubicin Glioma (Cell Line: SF-268) [7]
Topotecan + Valrubicin DCKQ60M Valrubicin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Valrubicin DCPKN3I Valrubicin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Valrubicin DCCZJ9E Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Valrubicin DCGZ4UR Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Valrubicin DCPLGVB Valrubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Valrubicin DC3ERO1 Valrubicin Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + GSK525762 DCKFUQC GSK525762 Adenocarcinoma (Cell Line: OVCAR3) [7]
Topotecan + GSK525762 DCSHDZ1 GSK525762 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + GSK525762 DC7X0ZU GSK525762 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + GSK525762 DCNAE5D GSK525762 Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + Trimethobenzamide DC5D7PT Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Maprotiline DCV5BZ5 Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Cisplatin DCUIX3F Cisplatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Cisplatin DC1G946 Cisplatin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Cisplatin DC86GDT Cisplatin Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Cisplatin DCV7E7B Cisplatin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Cisplatin DCJMFL3 Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Cisplatin DCC8AX9 Cisplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Cisplatin DC23SIZ Cisplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Cisplatin DCEKXYK Cisplatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Theophylline DCFNGTV Theophylline Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Chlorambucil DCGXBMU Chlorambucil Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Chlorambucil DCS089T Chlorambucil Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Chlorambucil DCUAR0R Chlorambucil Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Chlorambucil DCM0ZKX Chlorambucil Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Chlorambucil DCZIXZJ Chlorambucil Melanoma (Cell Line: UACC-257) [7]
Topotecan + Chlorambucil DCHCMSY Chlorambucil Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Chlorambucil DCK7GDZ Chlorambucil Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Chlorambucil DCIGNLJ Chlorambucil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Chlorambucil DC6LF8L Chlorambucil Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Amantadine DCGPFG8 Amantadine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Sorafenib DCVBGAT Sorafenib Adenocarcinoma (Cell Line: A427) [7]
Topotecan + Sorafenib DC0OWBE Sorafenib Adenocarcinoma (Cell Line: NCIH520) [7]
Topotecan + Sorafenib DCYNBW8 Sorafenib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Sorafenib DCSMTZS Sorafenib Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + Sorafenib DCA7TT1 Sorafenib Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Sorafenib DCS3NH5 Sorafenib Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Sorafenib DC2T98X Sorafenib Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Sorafenib DCAWWMX Sorafenib Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + Sorafenib DCSBLHZ Sorafenib Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Sorafenib DCQHUVS Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + Sorafenib DCBQ211 Sorafenib Germ cell tumour (Cell Line: PA1) [7]
Topotecan + Sorafenib DCBUT1Q Sorafenib Malignant melanoma (Cell Line: HT144) [7]
Topotecan + Sorafenib DC0B1GW Sorafenib Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + Sorafenib DC058K8 Sorafenib Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Sorafenib DC3K6EY Sorafenib Mesothelioma (Cell Line: MSTO) [7]
Topotecan + Sorafenib DC19EV7 Sorafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Sorafenib DCV4MVM Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [7]
Topotecan + Sorafenib DC8G29P Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Sorafenib DCMFU3T Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Sorafenib DCWY8KH Sorafenib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Sorafenib DCX5QKC Sorafenib Prostate carcinoma (Cell Line: VCAP) [7]
Topotecan + ER819762 DCULSLI ER819762 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + ER819762 DCKR9O8 ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + ER819762 DCFWVSQ ER819762 Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + ER819762 DCRWD1J ER819762 Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + ER819762 DCIJT1D ER819762 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + ER819762 DCRZCFO ER819762 Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + ER819762 DCRP14I ER819762 Glioma (Cell Line: SF-268) [7]
Topotecan + ER819762 DC9XXVI ER819762 Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + ER819762 DCGKBMX ER819762 Melanoma (Cell Line: UACC-257) [7]
Topotecan + ER819762 DCL417N ER819762 Melanoma (Cell Line: MALME-3M) [7]
Topotecan + ER819762 DCBGKWO ER819762 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + ER819762 DCGFT0L ER819762 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + ER819762 DCMCFY4 ER819762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + ER819762 DC4X5YX ER819762 Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + ER819762 DCZWT21 ER819762 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + ER819762 DCKE4C0 ER819762 Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Hyodeoxycholic acid DCCIXOU Hyodeoxycholic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Asenapine DCP0NC2 Asenapine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + MK-2206 DC5D6RM MK-2206 Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + MK-2206 DCNAVCI MK-2206 Adenocarcinoma (Cell Line: A427) [7]
Topotecan + MK-2206 DC0XMY0 MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [7]
Topotecan + MK-2206 DCP2R03 MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [7]
Topotecan + MK-2206 DCMKSFO MK-2206 Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + MK-2206 DC594EO MK-2206 Adenocarcinoma (Cell Line: HCT116) [7]
Topotecan + MK-2206 DC64U2C MK-2206 Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + MK-2206 DC1G82Y MK-2206 Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + MK-2206 DC6F4NY MK-2206 Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + MK-2206 DC8OH29 MK-2206 Germ cell tumour (Cell Line: PA1) [7]
Topotecan + MK-2206 DCKQZHI MK-2206 Malignant melanoma (Cell Line: SKMEL30) [7]
Topotecan + MK-2206 DC44EG3 MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + MK-2206 DCOL852 MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Romidepsin DC1Q4RP Romidepsin Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Romidepsin DCGX23B Romidepsin Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Romidepsin DCTQERC Romidepsin Glioma (Cell Line: SF-268) [7]
Topotecan + Romidepsin DC2HXKH Romidepsin Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Topotecan + Romidepsin DCYMPP2 Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Romidepsin DCPTY55 Romidepsin Malignant melanoma (Cell Line: LOX IMVI) [7]
Topotecan + Romidepsin DC6K40J Romidepsin Melanoma (Cell Line: UACC-257) [7]
Topotecan + Romidepsin DCIXHNP Romidepsin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Romidepsin DCNI3UD Romidepsin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Romidepsin DC7B60V Romidepsin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Romidepsin DCBIIBK Romidepsin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Romidepsin DCAJ5ZS Romidepsin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Romidepsin DC82IOA Romidepsin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Romidepsin DCZ1QIP Romidepsin Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Azacitidine DCY4PJT Azacitidine Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Azacitidine DCXTSI9 Azacitidine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Azacitidine DCGKR0K Azacitidine Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Azacitidine DC5MLQ6 Azacitidine Amelanotic melanoma (Cell Line: M14) [7]
Topotecan + Azacitidine DC9U3DI Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Azacitidine DCD3AFH Azacitidine Glioma (Cell Line: SF-268) [7]
Topotecan + Azacitidine DCZKPJS Azacitidine Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Azacitidine DCBKSJZ Azacitidine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Azacitidine DC4ADYF Azacitidine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Azacitidine DCDLA69 Azacitidine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Azacitidine DCY63GW Azacitidine Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Azacitidine DC7U3BL Azacitidine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Pomalidomide DCN1R4Y Pomalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Pomalidomide DCHHIVH Pomalidomide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Pomalidomide DCRFHGF Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Pomalidomide DCMT127 Pomalidomide Glioblastoma (Cell Line: SNB-75) [7]
Topotecan + Pomalidomide DC6R49Q Pomalidomide Glioma (Cell Line: SF-268) [7]
Topotecan + Pomalidomide DCE3HMW Pomalidomide Glioma (Cell Line: SF-295) [7]
Topotecan + Pomalidomide DCUTGBS Pomalidomide Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Pomalidomide DCOS4WV Pomalidomide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Pomalidomide DCQFJWY Pomalidomide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Pomalidomide DC7EW3X Pomalidomide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Pomalidomide DC6OD2X Pomalidomide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Pomalidomide DCMHXOD Pomalidomide Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + Pomalidomide DC17JQL Pomalidomide Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Vinflunine DCQBY12 Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Vinflunine DCMMKFW Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Vinflunine DCV0J6X Vinflunine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Vinflunine DCKQBK8 Vinflunine Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Spironolactone DCC40FQ Spironolactone Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Mercaptopurine DCGCVGN Mercaptopurine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Mercaptopurine DC8KV7I Mercaptopurine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Mercaptopurine DCTF9JG Mercaptopurine Glioblastoma (Cell Line: SNB-75) [7]
Topotecan + Mercaptopurine DCGDNB9 Mercaptopurine Glioma (Cell Line: SF-268) [7]
Topotecan + Mercaptopurine DC7OOVN Mercaptopurine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Mercaptopurine DCJ21PM Mercaptopurine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Mercaptopurine DC0H5Z0 Mercaptopurine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Hydralazine DCWCWLX Hydralazine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Mepacrine DC84DAM Mepacrine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Mepacrine DC72BE4 Mepacrine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Mepacrine DCFSTFO Mepacrine Glioma (Cell Line: SF-268) [7]
Topotecan + Mepacrine DCS8PZ0 Mepacrine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Mepacrine DCK7TVC Mepacrine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Mepacrine DCRCP4V Mepacrine Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Mepacrine DCOLQPP Mepacrine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Mepacrine DCP8HZJ Mepacrine Renal cell carcinoma (Cell Line: UO-31) [7]
Topotecan + Taxol DC5LBZC Taxol Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Taxol DC4LJ2S Taxol Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Taxol DC68S58 Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Cisatracurium DCC0WN0 Cisatracurium Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Mefloquine DC2WBD4 Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Lacosamide DC4R1QU Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Fludarabine DCY11HO Fludarabine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Fludarabine DCP1CR7 Fludarabine Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Fludarabine DC6SPDM Fludarabine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Fludarabine DCHMH3D Fludarabine Glioblastoma (Cell Line: SNB-75) [7]
Topotecan + Fludarabine DCI6LN4 Fludarabine Glioma (Cell Line: SF-268) [7]
Topotecan + Fludarabine DCQBQOA Fludarabine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Fludarabine DC8154U Fludarabine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Fludarabine DC0C227 Fludarabine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Fludarabine DCMO7YH Fludarabine Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Sumatriptan DCPR78O Sumatriptan Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + PMID28870136-Compound-43 DCHZ9D5 PMID28870136-Compound-43 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + PMID28870136-Compound-43 DCFPUB2 PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + PMID28870136-Compound-43 DC0B5IC PMID28870136-Compound-43 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + FORMESTANE DCTYCRH FORMESTANE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + FORMESTANE DC14WDK FORMESTANE Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + FORMESTANE DCLDC9L FORMESTANE Astrocytoma (Cell Line: SNB-19) [7]
Topotecan + FORMESTANE DC4ZZLP FORMESTANE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + FORMESTANE DCVM5Y8 FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + FORMESTANE DCJR6PN FORMESTANE Melanoma (Cell Line: MALME-3M) [7]
Topotecan + FORMESTANE DC1C0XW FORMESTANE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + FORMESTANE DCT6INL FORMESTANE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + FORMESTANE DC187FX FORMESTANE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + FORMESTANE DCR1TP8 FORMESTANE Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + FORMESTANE DCSX4TJ FORMESTANE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + FORMESTANE DC1EN9T FORMESTANE Prostate carcinoma (Cell Line: PC-3) [7]
Topotecan + FORMESTANE DC8GRPV FORMESTANE Renal cell carcinoma (Cell Line: SN12C) [7]
Topotecan + Estramustine DCZG5L8 Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Estramustine DCKIVSW Estramustine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Estramustine DC8BUUO Estramustine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Estramustine DC5EJRJ Estramustine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Estramustine DCNLDCK Estramustine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Estramustine DCGR9UT Estramustine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Digitoxin DCSDBKT Digitoxin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Digitoxin DC053EN Digitoxin Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Digitoxin DCDY80T Digitoxin Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Digitoxin DC12I92 Digitoxin Glioma (Cell Line: SF-268) [7]
Topotecan + Digitoxin DC120SR Digitoxin Lung adenocarcinoma (Cell Line: EKVX) [7]
Topotecan + Digitoxin DCS4XV9 Digitoxin Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Digitoxin DCGRATT Digitoxin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Topotecan + Digitoxin DC1770M Digitoxin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Digitoxin DCTUAY5 Digitoxin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Digitoxin DCUSFKC Digitoxin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Topotecan + Digitoxin DCTHN3V Digitoxin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Topotecan + Cerivastatin DCF9IOS Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Busulfan DCL5141 Busulfan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Busulfan DC5PCH6 Busulfan Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Busulfan DCFXNOM Busulfan Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Topotecan + Busulfan DCHL8UJ Busulfan Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Busulfan DCVB16S Busulfan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Topotecan + Busulfan DC8I515 Busulfan Glioma (Cell Line: SF-268) [7]
Topotecan + Busulfan DC9H4E9 Busulfan Melanoma (Cell Line: MALME-3M) [7]
Topotecan + Busulfan DC2P3HY Busulfan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Topotecan + Busulfan DCOBW8T Busulfan Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Topotecan + Aciclovir DC9LRSK Aciclovir Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Enoxacin DC0MZ06 Enoxacin Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Albendazole DCAZKEA Albendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + AS-1949490 DC5THB3 AS-1949490 Chronic myelogenous leukemia (Cell Line: KBM-7) [7]
Topotecan + Dasatinib DCK1CBI Dasatinib Adenocarcinoma (Cell Line: CAOV3) [7]
Topotecan + Dasatinib DCGGTY9 Dasatinib Adenocarcinoma (Cell Line: A427) [7]
Topotecan + Dasatinib DCMGSXR Dasatinib Adenocarcinoma (Cell Line: A549) [7]
Topotecan + Dasatinib DC665WP Dasatinib Adenocarcinoma (Cell Line: DLD1) [7]
Topotecan + Dasatinib DCQZ368 Dasatinib Adenocarcinoma (Cell Line: HT29) [7]
Topotecan + Dasatinib DCZX7IT Dasatinib Adenocarcinoma (Cell Line: SW-620) [7]
Topotecan + Dasatinib DCTEV8J Dasatinib Adenocarcinoma (Cell Line: HCC-2998) [7]
Topotecan + Dasatinib DC6SF5V Dasatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Topotecan + Dasatinib DCHYVVA Dasatinib Amelanotic melanoma (Cell Line: A2058) [7]
Topotecan + Dasatinib DC5KDIG Dasatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Topotecan + Dasatinib DCDIODJ Dasatinib Anaplastic large cell lymphoma (Cell Line: SR) [7]
Topotecan + Dasatinib DCBNJZS Dasatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Topotecan + Dasatinib DCTPCTE Dasatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Topotecan + Dasatinib DCKBQ8Y Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [7]
Topotecan + Dasatinib DCYZ3XQ Dasatinib Germ cell tumour (Cell Line: PA1) [7]
Topotecan + Dasatinib DCJ9IQR Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Topotecan + Dasatinib DCCR1L5 Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Topotecan + Dasatinib DCNRRB4 Dasatinib Malignant melanoma (Cell Line: A375) [7]
Topotecan + Dasatinib DC70MC4 Dasatinib Malignant melanoma (Cell Line: UACC62) [7]
Topotecan + Dasatinib DCY20TC Dasatinib Mesothelioma (Cell Line: MSTO) [7]
Topotecan + Dasatinib DCUK2AM Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [7]
Topotecan + Dasatinib DCXPPPJ Dasatinib Prostate carcinoma (Cell Line: VCAP) [7]
Trifluridine + Topotecan DCIS98T Trifluridine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Trifluridine + Topotecan DCX7OOH Trifluridine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Trifluridine + Topotecan DCQU7QP Trifluridine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Trifluridine + Topotecan DCNGG9H Trifluridine Glioblastoma (Cell Line: SNB-75) [5]
Trifluridine + Topotecan DC9DMAX Trifluridine Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Trifluridine + Topotecan DCFZHPF Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Trifluridine + Topotecan DC908FG Trifluridine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Trifluridine + Topotecan DCV3TA5 Trifluridine Lung adenocarcinoma (Cell Line: EKVX) [7]
Trifluridine + Topotecan DC78DT8 Trifluridine Melanoma (Cell Line: UACC-257) [7]
Trifluridine + Topotecan DCTIP5W Trifluridine Melanoma (Cell Line: MALME-3M) [7]
Trifluridine + Topotecan DCGHFEW Trifluridine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Uracil mustard + Topotecan DCLEZ56 Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Uracil mustard + Topotecan DCM689G Uracil mustard Astrocytoma (Cell Line: SNB-19) [5]
Uracil mustard + Topotecan DCW9PTO Uracil mustard Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Uracil mustard + Topotecan DCSI7U2 Uracil mustard Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Uracil mustard + Topotecan DCS3P7O Uracil mustard Glioblastoma (Cell Line: SNB-75) [5]
Uracil mustard + Topotecan DCRJFVO Uracil mustard Glioma (Cell Line: SF-295) [5]
Uracil mustard + Topotecan DCWEVZI Uracil mustard Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Uracil mustard + Topotecan DCERK8S Uracil mustard Renal cell carcinoma (Cell Line: SN12C) [5]
Uracil mustard + Topotecan DCKJQDA Uracil mustard Colon adenocarcinoma (Cell Line: COLO 205) [6]
Uracil mustard + Topotecan DCQRC15 Uracil mustard Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Uracil mustard + Topotecan DCQQA7A Uracil mustard Adenocarcinoma (Cell Line: OVCAR3) [7]
Uracil mustard + Topotecan DCOR628 Uracil mustard Adenocarcinoma (Cell Line: A549) [7]
Uracil mustard + Topotecan DCKR08Y Uracil mustard Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Uracil mustard + Topotecan DCB2HQT Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Uracil mustard + Topotecan DCAQWNQ Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Uracil mustard + Topotecan DCLVV4D Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Uracil mustard + Topotecan DCROFWZ Uracil mustard Lung adenocarcinoma (Cell Line: EKVX) [7]
Uracil mustard + Topotecan DCFLULP Uracil mustard Malignant melanoma (Cell Line: LOX IMVI) [7]
Uracil mustard + Topotecan DC5ZTKW Uracil mustard Melanoma (Cell Line: MALME-3M) [7]
Uracil mustard + Topotecan DC1PNPK Uracil mustard Melanoma (Cell Line: UACC-257) [7]
Uracil mustard + Topotecan DCTU1V8 Uracil mustard Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Uracil mustard + Topotecan DC0VX0V Uracil mustard Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Uracil mustard + Topotecan DCR72TA Uracil mustard Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Uracil mustard + Topotecan DCAE3ZW Uracil mustard Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vandetanib + Topotecan DCPZ987 Vandetanib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Vandetanib + Topotecan DCPI7RJ Vandetanib Carcinoma (Cell Line: MCF7) [6]
Vandetanib + Topotecan DCB0YTR Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Vandetanib + Topotecan DCLO0F7 Vandetanib Adenocarcinoma (Cell Line: A549) [7]
Vandetanib + Topotecan DCONJA4 Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Vandetanib + Topotecan DCMDN70 Vandetanib Astrocytoma (Cell Line: SNB-19) [7]
Vandetanib + Topotecan DCNG44A Vandetanib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Vandetanib + Topotecan DC4UJV2 Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Vandetanib + Topotecan DCUWYGV Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Vandetanib + Topotecan DCQHZ5W Vandetanib Glioma (Cell Line: SF-268) [7]
Vandetanib + Topotecan DCDXTRV Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Vandetanib + Topotecan DCQT7GZ Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Vandetanib + Topotecan DCWVQZI Vandetanib Melanoma (Cell Line: MALME-3M) [7]
Vandetanib + Topotecan DCV2CSN Vandetanib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Vandetanib + Topotecan DCETUDQ Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Vandetanib + Topotecan DCID18C Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Vandetanib + Topotecan DC38EKR Vandetanib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vemurafenib + Topotecan DCXQC1R Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Vemurafenib + Topotecan DCTLIVH Vemurafenib Carcinoma (Cell Line: RXF 393) [6]
Vemurafenib + Topotecan DCK8IAJ Vemurafenib Carcinoma (Cell Line: MCF7) [6]
Vemurafenib + Topotecan DCOISCH Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [6]
Vemurafenib + Topotecan DC2PPXA Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Vemurafenib + Topotecan DCL88PK Vemurafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Vemurafenib + Topotecan DCQ8G3T Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Vemurafenib + Topotecan DCWOCOK Vemurafenib Glioma (Cell Line: SF-268) [7]
Vemurafenib + Topotecan DCDAQG5 Vemurafenib Melanoma (Cell Line: MALME-3M) [7]
Vemurafenib + Topotecan DCBMHRS Vemurafenib Melanoma (Cell Line: UACC-257) [7]
Vemurafenib + Topotecan DCB91CN Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Vemurafenib + Topotecan DCTOU8B Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Vemurafenib + Topotecan DCD4K9X Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vemurafenib + Topotecan DCIULU8 Vemurafenib Renal cell carcinoma (Cell Line: UO-31) [7]
Vismodegib + Topotecan DCXS1RK Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [6]
Vismodegib + Topotecan DCG1269 Vismodegib Carcinoma (Cell Line: MCF7) [6]
Vismodegib + Topotecan DCYGRZG Vismodegib Adenocarcinoma (Cell Line: DU-145) [7]
Vismodegib + Topotecan DC7ZDZ0 Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Vismodegib + Topotecan DCVQ0QS Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Vismodegib + Topotecan DCJSRHO Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Vismodegib + Topotecan DC9DK48 Vismodegib Glioma (Cell Line: SF-268) [7]
Vismodegib + Topotecan DC2GD3C Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [7]
Vismodegib + Topotecan DC2WV4I Vismodegib Melanoma (Cell Line: MALME-3M) [7]
Vismodegib + Topotecan DCS5CC3 Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Vismodegib + Topotecan DCJT144 Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Vismodegib + Topotecan DCHAKFK Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Vismodegib + Topotecan DCA0Q62 Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vismodegib + Topotecan DCN1T6T Vismodegib Renal cell carcinoma (Cell Line: SN12C) [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1416 DrugCom(s)
22 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
ABT-888 + Topotecan DC0XC45 ABT-888 Ovarian Cancer [8]
Cyclophosphamide + Topotecan DCCDWAH Cyclophosphamide Neoplasm [9]
Erlotinib + Topotecan DC9L4H9 Erlotinib Metastatic Solid Tumor [10]
Everolimus + Topotecan DCLVR0I Everolimus Endometrial Cancer [11]
Gefitinib + Topotecan DC7V5UU Gefitinib Ovarian Cancer [12]
Gemcitabine + Topotecan DCLE5WV Gemcitabine Ovarian Cancer [13]
Lapatinib + Topotecan DC6UAXV Lapatinib Ovarian Cancer [14]
ME-344 + Topotecan DCZGTSY ME-344 Solid Tumors [15]
Olaparib + Topotecan DC3C1Y8 Olaparib Malignant Solid Tumors [16]
Pazopanib + Topotecan DC0ZSZ6 Pazopanib Gynecologic Tumors [17]
Pazopanib + Topotecan DCHNPYR Pazopanib Solid Tumours [18]
Temozolomide + Topotecan DCBFU2D Temozolomide Central Nervous System Tumors [19]
Temozolomide + Topotecan DCK4J5F Temozolomide Central Nervous System (CNS) Metastases [20]
Topotecan + Temsirolimus DCJGINW Temsirolimus Genital Neoplasms, Female [21]
Topotecan + UCN-01 DCXOVQG UCN-01 Fallopian Tube Cancer [22]
Topotecan + Vinorelbine DCYHSU1 Vinorelbine Lung Cancer [23]
Topotecan + VX-970 DCQ5WST VX-970 Carcinoma, Non-Small -Cell Lung [24]
Amrubicin + Topotecan DCEFNQ3 Amrubicin Small Cell Lung Cancer (SCLC) [25]
Cyclophosphamide + Topotecan DCNHQ9W Cyclophosphamide Neuroblastoma [26]
Rivoceranib + Topotecan DC41TML Rivoceranib Small Cell Lung Cancer [27]
Al3818 + Topotecan DCUXKE6 Al3818 Small Cell Lung Cancer [28]
Topotecan + Irinotecan DCEDVX5 Irinotecan Relapsed Small Cell Lung Cancer [29]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)

References

1 Topotecan FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7101).
3 Plant-derived compounds in clinical trials. Drug Discov Today. 2008 Feb;13(3-4):161-71.
4 ClinicalTrials.gov (NCT00765973) Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. U.S. National Institutes of Health.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
7 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
8 ClinicalTrials.gov (NCT01690598) Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
9 ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.
10 ClinicalTrials.gov (NCT00611468) Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
11 ClinicalTrials.gov (NCT00703807) Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
12 ClinicalTrials.gov (NCT00317772) Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
13 ClinicalTrials.gov (NCT00429559) Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
14 ClinicalTrials.gov (NCT00436644) Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
15 ClinicalTrials.gov (NCT02100007) ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors
16 ClinicalTrials.gov (NCT00516438) Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
17 ClinicalTrials.gov (NCT00800345) Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
18 ClinicalTrials.gov (NCT00732420) Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
19 ClinicalTrials.gov (NCT00109798) Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
20 ClinicalTrials.gov (NCT01736800) Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
21 ClinicalTrials.gov (NCT00523432) A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
22 ClinicalTrials.gov (NCT00045175) UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
23 ClinicalTrials.gov (NCT00287963) Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
24 ClinicalTrials.gov (NCT02487095) Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
25 ClinicalTrials.gov (NCT01904253) A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
26 ClinicalTrials.gov (NCT00601003) Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
27 ClinicalTrials.gov (NCT02980809) Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
28 ClinicalTrials.gov (NCT04073550) Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
29 ClinicalTrials.gov (NCT05153239) Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)